The EU grants Pfizer (PFE) marketing approval for its Inlyta drug for advanced kidney cancer in...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

The EU grants Pfizer (PFE) marketing approval for its Inlyta drug for advanced kidney cancer in patients who who haven't responded to prior treatments with two other drugs, sunitinib or a cytokine. The authorization adds to those from the FDA, Switzerland, Japan, Canada, Australia and South Korea. (PR)